The health and budget impact of sodium-glucose co-transporter-2 inhibitors (SGLT2is) in the Netherlands

  • Alexander V. van Schoonhoven (Creator)
  • Marcel H. Schöttler (Creator)
  • Erik Serné (Creator)
  • Patrick P. G. Schrömbges (Creator)
  • Maarten J. Postma (Creator)
  • Cornelis Boersma (Creator)

Dataset

Description

Type-2 Diabetes Mellitus (T2DM) increases both the patient risk of cardiovascular disease (CVD) and renal outcomes, such as chronic kidney disease (CKD). Recent clinical trials of the glucose-lowering drug-class of sodium-glucose co-transporter-2 inhibi...
Date made available2023
PublisherTaylor & Francis

Access Dataset

Cite this